Myeloproliferative neoplasms (MPN) are a rare form of blood cancer. Though most people don’t know a lot about, approximately 20,000 people develop MPNs each year. Here are the basics you can explain to a concerned patient.
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Retrospective analysis sought to determine incidence of hip and vertebral fractures in patients with MPN compared with that of the general population.
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
Spleen stiffness was found to be correlated with the extent of bone marrow fibrosis, as well as clinical outcome, in patients with MPNs.
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.
Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.
